Jialin Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jialin Luo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Guoping Cheng
Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China
2 shared publications - Linfeng Zheng
Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China
2 shared publications - Luying Liu
Zhejiang cancer hospital 10 , Hangzhou, China
2 shared publications - Yanru Feng
Calgary, Alberta
2 shared publications - Yuan Zhu
Department of Radiation Oncology, Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), The Cancer Hospital of the University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou, China
2 shared publications - Peng Liu
Accelerator Division, Institute of High Energy Physics, Chinese Academy of Sciences, No. 19B Yuquan Road, Beijing 100049
1 shared publication
Latest Publications
- Open Access
- 14 February 2022
- Published by Springer Nature in Discover Oncology
- Vol. 13 (1) , 1-9
Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer
Purpose: To evaluate the role of programmed death-ligand 1 (PD-L1) and mammalian target of rapamycin (mTOR) signaling pathway in locally advanced rectal cancer (LARC).Methods: Between February 2012 and February 2018, 103 patients with LARC treated by neoadjuvant chemoradiotherapy (neoCRT) and total mesorectal excision (TME) were included. PD-L1, mTOR and p-mTOR of pair-matched pre-neoCRT biopsies and post-neoCRT surgical tissue were evaluated by immunohistochemistry.Results: The mean combined positive score (CPS), tumor proportion score (TPS) and immune cell score (IC) of pre-neoCRT were 2.24 (0–70), 1.87 (0–70) and 0.67 (0–10), respectively. The mean CPS, TPS and IC of post-neoCRT were 2.19 (0–80), 1.38 (0–80) and 1.60 (0–20), respectively. Significant difference was observed in terms of IC between pre-neoCRT and post-neoCRT (p = 0.010). The 5-year disease-free survival (DFS) rate of the whole group was 62.4%. Multivariate analysis by Cox model indicated that pre-neoCRT TPS [hazard ratio (HR) 1.052, 95% confidence interval (CI) 1.020–1.086, p = 0.001] and post-neoCRT CPS (HR 0.733, 95% CI 0.555–0.967, p = 0.028) were associated with DFS. In the 89 patients without pathological complete response, p-mTOR and IC were upregulated after neoCRT.Conclusions: For patients with LARC treated by neoCRT and TME, p-mTOR and IC were upregulated after neoCRT. Pre-neoCRT TPS and post-neoCRT CPS were independent prognostic predictors of DFS.
- 14 February 2022
- Published by Springer Nature in Discover Oncology
- Vol. 13 (1) , 1-9
Open AccessProgrammed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer
Purpose: To evaluate the role of programmed death-ligand 1 (PD-L1) and mammalian target of rapamycin (mTOR) signaling pathway in locally advanced rectal cancer (LARC).Methods: Between February 2012 and February 2018, 103 patients with LARC treated by neoadjuvant chemoradiotherapy (neoCRT) and total mesorectal excision (TME) were included. PD-L1, mTOR and p-mTOR of pair-matched pre-neoCRT biopsies and post-neoCRT surgical tissue were evaluated by immunohistochemistry.Results: The mean combined positive score (CPS), tumor proportion score (TPS) and immune cell score (IC) of pre-neoCRT were 2.24 (0–70), 1.87 (0–70) and 0.67 (0–10), respectively. The mean CPS, TPS and IC of post-neoCRT were 2.19 (0–80), 1.38 (0–80) and 1.60 (0–20), respectively. Significant difference was observed in terms of IC between pre-neoCRT and post-neoCRT (p = 0.010). The 5-year disease-free survival (DFS) rate of the whole group was 62.4%. Multivariate analysis by Cox model indicated that pre-neoCRT TPS [hazard ratio (HR) 1.052, 95% confidence interval (CI) 1.020–1.086, p = 0.001] and post-neoCRT CPS (HR 0.733, 95% CI 0.555–0.967, p = 0.028) were associated with DFS. In the 89 patients without pathological complete response, p-mTOR and IC were upregulated after neoCRT.Conclusions: For patients with LARC treated by neoCRT and TME, p-mTOR and IC were upregulated after neoCRT. Pre-neoCRT TPS and post-neoCRT CPS were independent prognostic predictors of DFS.
- Open Access
- 1 January 2022
- Published by The Korean Surgical Society in Annals of Surgical Treatment and Research
- Vol. 102 (3) , 153-158
Glasgow prognostic score and combined positive score for locally advanced rectal cancer
Feng Y, et al. Ann Surg Treat Res. 2022 Mar;102(3):153-158. https://doi.org/10.4174/astr.2022.102.3.153
- 1 January 2022
- Published by The Korean Surgical Society in Annals of Surgical Treatment and Research
- Vol. 102 (3) , 153-158
Open AccessGlasgow prognostic score and combined positive score for locally advanced rectal cancer
Feng Y, et al. Ann Surg Treat Res. 2022 Mar;102(3):153-158. https://doi.org/10.4174/astr.2022.102.3.153